JoAnn Scatina

Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4

S. Ball, JoAnn Scatina, John Y. Kao et al. · Clinical Pharmacology & Therapeutics · 1999 · 233 citations

Life Sciences, Genetics, Molecular Genetics +16

Metabolic disposition of¹⁴C-venlafaxine in mouse, rat, dog, rhesus monkey and man

Stanley R. Howell, G. E. M. Husbands, JoAnn Scatina et al. · Xenobiotica · 1993 · 122 citations

Medicine, Pharmacokinetics, Pharmacology +13

Nuclear Magnetic Resonance Spectroscopy as a Quantitative Tool To Determine the Concentrations of Biologically Produced Metabolites: Implications in Metabolites in Safety Testing

Robert Espina, Linning Yu, Jianyao Wang et al. · Chemical Research in Toxicology · 2008 · 113 citations

Life Sciences, Biochemistry, Toxicology +17

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2

S. Ball, Dennis Ahern, JoAnn Scatina et al. · British Journal of Clinical Pharmacology · 1997 · 104 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Obtaining Exposures of Metabolites in Preclinical Species through Plasma Pooling and Quantitative NMR: Addressing Metabolites in Safety Testing (MIST) Guidance without Using Radiolabeled Compounds and Chemically Synthesized Metabolite Standards

Karthick Vishwanathan, Kathlene Babalola, Jack Wang et al. · Chemical Research in Toxicology · 2008 · 99 citations

Life Sciences, Pharmacokinetics, Pharmacology +17